Appendix 4C & Q1 FY22 Activities Report
Filed with ASX · · 8 pages · English
MELBOURNE, 29 October 2021: Anatara Lifesciences (ASX: ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals, is pleased to provide this activities report for the quarter ending 30 September 2021 (Q1 FY22), along with the Company’sAppendix 4C cash flow report. Commenting on the quarter, CEO Steve Lydeamore said,“Anatara is pleasedwith the developments th
Anatara Lifesciences Ltd on 6ix
Story so far
Earlier from Anatara Lifesciences
- Anatara Lifesciences Limited (ASX: ANR) Annual Report to Shareholders
- Investor Presentation
- Appendix 4E & Financial Report 30 June 2021
- Anatara Lifesciences Limited (ASX: ANR) Launches IBS-D Clinical Trial Recruitment Website
- Successful Piglet Study
Later from Anatara Lifesciences
- AGM CEO Presentation
- Chairmans Address to Shareholders
- Application for quotation of securities - ANR
- Notification regarding unquoted securities - ANR
- Change of Director's Interest Notice
Follow Anatara Lifesciences into a list and get an email when it puts out news.
Follow Anatara Lifesciences